Synta Pharmaceuticals (SNTA) Announces Launch of Proprietary Small Molecule Hsp90-inhibitor Drug Conjugate Platform
9/11/2013 9:26:48 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the launch of its Hsp90-inhibitor Drug Conjugate (HDC) platform, which leverages the Company’s expertise in chaperone biology and medicinal chemistry to create a new class of anti-cancer therapies. Current oncology therapeutics generally fall into two categories: cytotoxic agents and molecularly targeted therapies. Cytotoxic agents are often broadly active, but have the disadvantage of high toxicity caused by damage to normal cells, which limits their utility. Drugs that target specific protein drivers of cancer cell growth are generally more tumor selective, yet often lead to tumor resistance via point mutations in their target (e.g. ALK, BRAF, EGFR inhibitors) or activation of alternative signaling pathways (e.g., MEK, ERK, or AKT upregulation).
Help employers find you! Check out all the jobs and post your resume.